Additional molecular and clinical evidence open the way to definitive IARC classification of the BRCA1 c.5332G > A (p.Asp1778Asn) variant

Angelo Minucci, Maurizio Lalle, Rossella De Leo, Giorgia Mazzuccato, Giovanni Scambia, Andrea Urbani, Anna Fagotti, Paola Concolino, Ettore Capoluongo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: In silico splicing analysis, a mini-gene assay and splicing data, obtained using RNA from blood samples, have shown that the BRCA1 c.5332G > A variant induces exon 21 skipping. However, despite these evidences, up to date, this variant is unclassified. The aim of this study is to provide further molecular and clinical evidence for the BRCA1 c.5332G > A variant in a patient with high grade serous ovarian carcinoma (HGSOC) to allow a definitive classification of this variant. Design and method: The effect of the BRCA1 c.5332G > A variant on RNA splicing was evaluated by amplifying regions of BRCA1 from the cDNA of the patient. Loss of heterozygosity (LOH) in tumor tissue was also investigated. Results: The c.5332G > A allele causes significantly aberrant splicing of the BRCA1 exon 21. Evaluation of the c.5332A allele in tumor tissue highlights a possible loss of heterozygosity, supporting her pathogenic effect. Conclusions: Our results regarding the c.5332G > A variant confirm that it contributed to predisposition and onset of ovarian carcinoma in the patient. We propose to classify this variant as ‘likely-pathogenic’ (class IV).

Original languageEnglish
Pages (from-to)54-58
Number of pages5
JournalClinical Biochemistry
Volume63
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Tumors
Exons
Loss of Heterozygosity
RNA
Tissue
Alleles
RNA Splicing
Carcinoma
Assays
Blood
Complementary DNA
Genes
Computer Simulation
Neoplasms

Keywords

  • Exon skipping
  • Hereditary ovarian cancer
  • Loss of heterozygosity
  • Splicing variant

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Additional molecular and clinical evidence open the way to definitive IARC classification of the BRCA1 c.5332G > A (p.Asp1778Asn) variant. / Minucci, Angelo; Lalle, Maurizio; De Leo, Rossella; Mazzuccato, Giorgia; Scambia, Giovanni; Urbani, Andrea; Fagotti, Anna; Concolino, Paola; Capoluongo, Ettore.

In: Clinical Biochemistry, Vol. 63, 01.01.2019, p. 54-58.

Research output: Contribution to journalArticle

@article{327dc3839a584c89bb30b9d939b8cd3e,
title = "Additional molecular and clinical evidence open the way to definitive IARC classification of the BRCA1 c.5332G > A (p.Asp1778Asn) variant",
abstract = "Objectives: In silico splicing analysis, a mini-gene assay and splicing data, obtained using RNA from blood samples, have shown that the BRCA1 c.5332G > A variant induces exon 21 skipping. However, despite these evidences, up to date, this variant is unclassified. The aim of this study is to provide further molecular and clinical evidence for the BRCA1 c.5332G > A variant in a patient with high grade serous ovarian carcinoma (HGSOC) to allow a definitive classification of this variant. Design and method: The effect of the BRCA1 c.5332G > A variant on RNA splicing was evaluated by amplifying regions of BRCA1 from the cDNA of the patient. Loss of heterozygosity (LOH) in tumor tissue was also investigated. Results: The c.5332G > A allele causes significantly aberrant splicing of the BRCA1 exon 21. Evaluation of the c.5332A allele in tumor tissue highlights a possible loss of heterozygosity, supporting her pathogenic effect. Conclusions: Our results regarding the c.5332G > A variant confirm that it contributed to predisposition and onset of ovarian carcinoma in the patient. We propose to classify this variant as ‘likely-pathogenic’ (class IV).",
keywords = "Exon skipping, Hereditary ovarian cancer, Loss of heterozygosity, Splicing variant",
author = "Angelo Minucci and Maurizio Lalle and {De Leo}, Rossella and Giorgia Mazzuccato and Giovanni Scambia and Andrea Urbani and Anna Fagotti and Paola Concolino and Ettore Capoluongo",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clinbiochem.2018.10.004",
language = "English",
volume = "63",
pages = "54--58",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Additional molecular and clinical evidence open the way to definitive IARC classification of the BRCA1 c.5332G > A (p.Asp1778Asn) variant

AU - Minucci, Angelo

AU - Lalle, Maurizio

AU - De Leo, Rossella

AU - Mazzuccato, Giorgia

AU - Scambia, Giovanni

AU - Urbani, Andrea

AU - Fagotti, Anna

AU - Concolino, Paola

AU - Capoluongo, Ettore

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: In silico splicing analysis, a mini-gene assay and splicing data, obtained using RNA from blood samples, have shown that the BRCA1 c.5332G > A variant induces exon 21 skipping. However, despite these evidences, up to date, this variant is unclassified. The aim of this study is to provide further molecular and clinical evidence for the BRCA1 c.5332G > A variant in a patient with high grade serous ovarian carcinoma (HGSOC) to allow a definitive classification of this variant. Design and method: The effect of the BRCA1 c.5332G > A variant on RNA splicing was evaluated by amplifying regions of BRCA1 from the cDNA of the patient. Loss of heterozygosity (LOH) in tumor tissue was also investigated. Results: The c.5332G > A allele causes significantly aberrant splicing of the BRCA1 exon 21. Evaluation of the c.5332A allele in tumor tissue highlights a possible loss of heterozygosity, supporting her pathogenic effect. Conclusions: Our results regarding the c.5332G > A variant confirm that it contributed to predisposition and onset of ovarian carcinoma in the patient. We propose to classify this variant as ‘likely-pathogenic’ (class IV).

AB - Objectives: In silico splicing analysis, a mini-gene assay and splicing data, obtained using RNA from blood samples, have shown that the BRCA1 c.5332G > A variant induces exon 21 skipping. However, despite these evidences, up to date, this variant is unclassified. The aim of this study is to provide further molecular and clinical evidence for the BRCA1 c.5332G > A variant in a patient with high grade serous ovarian carcinoma (HGSOC) to allow a definitive classification of this variant. Design and method: The effect of the BRCA1 c.5332G > A variant on RNA splicing was evaluated by amplifying regions of BRCA1 from the cDNA of the patient. Loss of heterozygosity (LOH) in tumor tissue was also investigated. Results: The c.5332G > A allele causes significantly aberrant splicing of the BRCA1 exon 21. Evaluation of the c.5332A allele in tumor tissue highlights a possible loss of heterozygosity, supporting her pathogenic effect. Conclusions: Our results regarding the c.5332G > A variant confirm that it contributed to predisposition and onset of ovarian carcinoma in the patient. We propose to classify this variant as ‘likely-pathogenic’ (class IV).

KW - Exon skipping

KW - Hereditary ovarian cancer

KW - Loss of heterozygosity

KW - Splicing variant

UR - http://www.scopus.com/inward/record.url?scp=85054715383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054715383&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2018.10.004

DO - 10.1016/j.clinbiochem.2018.10.004

M3 - Article

C2 - 30315757

AN - SCOPUS:85054715383

VL - 63

SP - 54

EP - 58

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

ER -